Is Evexia Lifecare overvalued or undervalued?

As of 8 October 2025, the valuation grade for Evexia Lifecare has moved from expensive to very expensive. The company is currently overvalued, as indicated by its high PE ratio of 216.70, an EV to EBIT of 276.15, and an EV to EBITDA of 208.63. In comparison, peers such as Castrol India and Gulf Oil Lubricants have significantly lower PE ratios of 20.74 and 16.09, respectively, highlighting the disparity in valuation.
The company's financial performance metrics, including a ROCE of 0.26% and a ROE of 0.31%, suggest limited profitability relative to its high valuation. Additionally, Evexia Lifecare's stock has underperformed against the Sensex over the past year, with a return of -49.50% compared to the Sensex's 0.17%, further reinforcing the notion that the stock is overvalued in the current market context.